Naiyer A. Rizvi, MD
Although study findings have identified tumor mutational burden (TMB) as an important factor in responses to cancer therapy, establishing a definition for expression of this biomarker and harmonizing assays to measure it have proved challenging, according to Naiyer A. Rizvi, MD.
Plasma assays for determining TMB are becoming more diagnostically relevant, said Rizvi, director of thoracic oncology and immunotherapeutics at the Herbert Irving Comprehensive Cancer Center in New York, New York.
What is important now is figuring out the respective values for determining high levels of TMB in each tumor type, since it has been determined that each disease may have its own cutoff for high TMB. Investigators in 1 analysis found that high TMB expression was regularly associated with better survival outcomes; however, the cutoff point for determining this level is not consistent across tumor types, assays, and clinical trials.
Rizvi reviewed recent TMB findings during a presentation at the European Society of Medical Oncology 2019 International Congress on Targeted Anticancer Therapies.
... to read the full story